Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM). Of the 1186 glioma patients who received chemotherapy ASI exposure improved OS (HR 0.82; 95% CI 0.71, 0.93; p = 0.003). When stratified by BEV exposure, a sub-analysis revealed further OS advantage for the BEV group (HR 0.75, 95% CI 0.62, 0.90; p = 0.002). In a second cohort of 181 rGBM patients who received BEV in varying dosages, ASI exposure conferred an OS advantage (HR 0.649; 95% CI 0.46, 0.92; p = 0.016). Moreover, patients with ASI exposure who received low-dose BEV treatment (AUC BEV < 3.6 mg wk/kg) had a significantly longer OS (median = 99 weeks; 95% CI 44.3, 205) than those without ASI (median OS = 55.6 weeks; 95% CI 37.7-73.7; p = 0.032). ASI use is associated with longer OS in glioma patients. Further survival advantage with ASI use was observed in rGBM patients receiving low-dose bevacizumab. These data warrant prospective evaluation of adding ASI to low-dose BEV treatment in GBM patients to improve the outcome of standard therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the results of two retrospective studies have shown that low-dose bevacizumab (<3.6 mg/kg per week) in combination with chemoradiotherapy confers a greater survival benefit than high-dose bevacizumab (5 mg/kg per week) in patients with glioblastoma74–77”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [75]
In the citing paper
“the results of a retrospective study demonstrated that patients with recurrent glioblastoma who were treated with bevacizumab and used angiotensin receptor blockers (ARBs) had prolonged overall survival compared with those who did not use ARBs (HR 0.65, 95% CI 0.46–0.92; P = 0.016), including the subgroup treated with low-dose bevacizumab (area under the curve for bevacizumab <3.6 mg/kg per week)7”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [75]
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 5×
“In addition, since preclinical studies found that ASIs can improve tumor perfusion, reducing tumor hypoxia and enhancing drug delivery [5, 11, 12, 15].”
BackgroundSelf-citationHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 3×
“In addition, since preclinical studies found that ASIs can improve tumor perfusion, reducing tumor hypoxia and enhancing drug delivery [5, 11, 12, 15].”
BackgroundSelf-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 2×
“In addition, since preclinical studies found that ASIs can improve tumor perfusion, reducing tumor hypoxia and enhancing drug delivery [5, 11, 12, 15].”
BackgroundSelf-citationDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733 · cited 2×
“In addition, since preclinical studies found that ASIs can improve tumor perfusion, reducing tumor hypoxia and enhancing drug delivery [5, 11, 12, 15].”
BackgroundSelf-citationThe renin–angiotensin system and cancer: old dog, new tricks
George, A. J., Thomas, W. G., & Hannan, R. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2945 · Cited by 525 · cited 1×
“Mounting preclinical and clinical evidence has implicated the renin-angiotensin system (RAS) as a major player in tumor malignancy, and that RAS inhibitors, such as ASIs, may augment currently approved therapies in various solid cancers [19].”
BackgroundCombining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508 · cited 1×
“The effect on OS with combined ASI and BEV exposure (with or without chemotherapy) falls in line with previously published theoretical predictions of the effects of drug dosage and baseline perfusion when utilizing these two classes of agents to simultaneously improve perfusion [23].”
ResultSelf-citationLevin, V. A., Silver, P., Hannigan, J., Wara, W. M., Gutin, P. H., Davis, R. L., & Wilson, C. B. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90096-3 · Cited by 401 · cited 1×
“Treatment advances for patients with GBM remain marginal with an 8–9% survival rate at 10 years [2].”
BackgroundSelf-citationBatchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy-Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 340 · cited 1×
“This effect is transient, occurring in a “window of normalization,” that is dependent on both treatment dose and duration; furthermore, low-dose antiangiogenic therapy may prove more efficacious in enhancing therapeutic outcome—especially in patient subsets stratified by perfusion status [5, 15, 17, 18].”
BackgroundSelf-citationLu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179 · cited 1×
“Based on VEGF-driven hypervascularity in GBM, antiangiogenic therapies emerged as a promising treatment strategy; however, despite encouraging delays in tumor progression and reduction of debilitating edema, randomized phase III trials have failed to show a benefit in OS [15, 16].”
BackgroundSelf-citationAngiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma
McKay, R. R., Rodriguez, G. E., Lin, X., Kaymakcalan, M. D., Hamnvik, O. R., Sabbisetti, V. S., Bhatt, R. S., Simantov, R., & Choueiri, T. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2332 · Cited by 137 · cited 1×
“Several retrospective clinical studies in non-CNS cancers have shown improved survival with ASIs, including but not limited to NSCLC, renal cell carcinoma, and hepatocellular carcinoma [13, 20, 21].”
BackgroundArrieta, O. G., Guevara, P., Escobar, E., García-Navarrete, R., Pineda, B., & Sotelo, J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602483 · Cited by 120 · cited 1×
“Indeed, AT1 inhibition by ASIs has been shown previously to reduce tumor VEGF levels, including in preclinical glioma models [24, 25].”
BackgroundAT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma
Rivera, E., Arrieta, O. G., Guevara, P., Duarte‐Rojo, A., & Sotelo, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2102 · Cited by 89 · cited 1×
“Indeed, AT1 inhibition by ASIs has been shown previously to reduce tumor VEGF levels, including in preclinical glioma models [24, 25].”
BackgroundFacciorusso, A., Del Prete, V., Crucinio, N., Muscatiello, N., Carr, B. I., Di Leo, A., & Barone, M. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12988 · Cited by 75 · cited 1×
“Several retrospective clinical studies in non-CNS cancers have shown improved survival with ASIs, including but not limited to NSCLC, renal cell carcinoma, and hepatocellular carcinoma [13, 20, 21].”
BackgroundLevin, V. A., Mendelssohn, N. D., Chan, J., Stovall, M. C., Peak, S. J., Yee, J. L., Hui, R. L., & Chen, D. M. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1693-x · Cited by 66 · cited 3×
“In the published study, we concluded that dosing BEV at half the standard dose for progressive/recurrent GBM was at least equivalent to or maybe better than standard dosing [6].”
BackgroundMethodSelf-citationLorgis, V., Maura, G., Coppa, G., Hassani, K., Taillandier, L., Chauffert, B., Apetoh, L., Ladoire, S., & Ghiringhelli, F. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0748-5 · Cited by 60
Liu, T. T., Achrol, A. S., Mitchell, L. A., Rodriguez, S. A., Feroze, A., Iv, M., Kim, C., Chaudhary, N., Gevaert, O., Stuart, J. M., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now270 · Cited by 56 · cited 1×
“This effect is transient, occurring in a “window of normalization,” that is dependent on both treatment dose and duration; furthermore, low-dose antiangiogenic therapy may prove more efficacious in enhancing therapeutic outcome—especially in patient subsets stratified by perfusion status [5, 15, 17, 18].”
BackgroundSteroid‐sparing effects of angiotensin‐ II inhibitors in glioblastoma patients
Carpentier, A. F., Ferrari, D., Bailon, O., Ursu, R., Banissi, C., Dubessy, A., Belin, C., & Lévy, C. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03766.x · Cited by 41
Impact of renin‐angiotensin system blockade on clinical outcome in glioblastoma
Januel, É., Ursu, R., Alkhafaji, A., Marantidou, A., Doridam, J., Belin, C., Lévy-Piedbois, C., & Carpentier, A. F. (2015) · European Journal of Neurology · doi:10.1111/ene.12746 · Cited by 40
Lombardi, G., Zustovich, F., Farina, P., Fiduccia, P., Puppa, A. D., Polo, V., Bertorelle, R., Gardiman, M. P., Banzato, A., Ciccarino, P., et al. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835aa5fd · Cited by 37
Menter, A. R., Carroll, N. M., Sakoda, L. C., Delate, T., Hornbrook, M. C., Jain, R. K., Kushi, L. H., Quinn, V. P., & Ritzwoller, D. P. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.07.008 · Cited by 37 · cited 3×
“Based on these observations and the suggestion that ASIs can improve survival of glioblastoma patients treated with bevacizumab [14] or NSCLC patients treated with carboplatin [13], we investigated whether glioma patients on cytotoxic chemotherapy and/or antiangiogenic agents have improved survival when under concomit…”
BackgroundSelf-citationImpact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients
Kourilsky, A., Bertrand, G., Ursu, R., Doridam, J., Barlog, C., Faillot, T., Mandonnet, E., Belin, C., Levy, C., & Carpentier, A. F. (2016) · Journal of Neurology · doi:10.1007/s00415-015-8016-9 · Cited by 27 · cited 1×
“Thus, via complementary anti-VEGF effects, ASI treatment may improve vascular perfusion and reduce edema in the tumor and peritumor brain [10].”
BackgroundNovel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses
Conroy, S., Wagemakers, M., Walenkamp, A., Kruyt, F. A. E., & den Dunnen, W. F. A. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2269-8 · Cited by 24
Murphy, J. E., Wo, J. Y.-L., Ferrone, C., Jiang, W., Yeap, B. Y., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Faris, J. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.386 · Cited by 23 · cited 1×
“Preliminary results from an ongoing prospective Phase II clinical trial in pancreatic cancer (NCT01821729) indicate that ASI combined with chemotherapy and radiation therapy doubled the resection rate of locally advanced disease and dramatically increased survival [22].”
Background
Research works printed but not linked: 1
- Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK (2015) Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33:1197–1213. doi: 10.1200/JCO.2014.55.9575 · DOI · Paper page
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationImproving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Self-citationNormalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Self-citationTargeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Self-citationGlioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Metadata
- Authors
- Levin, V. A., Chan, J., Datta, M., Yee, J. L., & Jain, R. K.
- Affiliations
- Kaiser Permanente (US)
- Tufts University (US)
- Harvard University (US)
- Corresponding author
- Levin, Victor A.
- Venue
- Journal of Neuro-Oncology
- Published
- 2017-06-19
- Volume
- 134
- Issue
- 2
- Pages
- 325-330
- ISSN
- 0167-594X (ISSN-L)
- 1573-7373
- OpenAlex
- W2655050774
- Cited by
- 51
- References
- 24
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 8 · 2017: 1
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Neuro-Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (P01CA080124, NIH-F31HL126449)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- renin-angiotensin system inhibitors, glioma, glioblastoma, recurrent glioblastoma, bevacizumab, overall survival, low-dose bevacizumab, cytotoxic chemotherapy, combination therapy
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Adult, Aged, Brain Neoplasms, Drug Therapy, Combination, Female, Glioma, Humans, Male, Neoplasm Recurrence, Local, Registries, Retrospective Studies, Proportional Hazards Models, Angiotensin Receptor Antagonists, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.